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Abstract
Background: The study examines differences regarding quality of life (QoL), mental health and illness beliefs between
in-centre haemodialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD/PD) patients. Differences are
examined between patients who recently commenced treatment compared to patients on long term treatment.
Methods: 144 End-Stage Renal Disease (ESRD) patients were recruited from three treatment units, of which 135
provided full data on the variables studied. Patients consisted of: a) 77 in-centre haemodialysis (HD) and 58 continuous
ambulatory peritoneal dialysis (CAPD/PD) patients, all currently being treated by dialysis for varied length of time.
Patients were compared for differences after being grouped into those who recently commenced treatment (< 4 years)
and those on long term treatment (> 4 years). Next, cases were selected as to form two equivalent groups of HD and
CAPD/PD patients in terms of length of treatment and sociodemographic variables. The groups consisted of: a) 41 in-
centre haemodialysis (HD) and b) 48 continuous ambulatory peritoneal dialysis (CAPD/PD) patients, fitting the selection
criteria of recent commencement of treatment and similar sociodemographic characteristics. Patient-reported
assessments included: WHOQOL-BREF, GHQ-28 and the MHLC, which is a health locus of control inventory.
Results: Differences in mean scores were mainly observed in the HD patients with > 4 years of treatment, providing
lower mean scores in the QoL domains of physical health, social relationships and environment, as well as in overall mental
health. Differences in CAPD/PD groups, between those in early and those in later years of treatment, were not found
to be large and significant. Concerning the analysis on equivalent groups derived from selection of cases, HD patients
indicated significantly lower mean scores in the QoL domain of environment and higher scores in the GHQ-28 subscales
of anxiety/insomnia and severe depression, indicating more symptoms in these areas of mental health. With regards to illness
beliefs, HD patients who recently commenced treatment provided higher mean scores in the dimension of internal health
locus of control, while CAPD/PD patients on long term treatment indicated higher mean scores in the dimension of
chance. Regarding differences in health beliefs between equivalent groups of HD and CAPD/PD patients, HD patients
focused more on the dimension of internal health locus of control.
Conclusion: The results provide evidence that patients in HD treatment modality, particularly those with many years
of treatment, were experiencing a more compromised QoL in comparison to CAPD/PD patients.
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Background
Populations facing chronic illness have been reported to
have poorer QoL and mental health including higher lev-
els of depression [1-3]. In this context, health services for
ill-health populations including End-Stage Renal Disease
(ESRD) have drawn attention to quality of life issues and
promotion of mental health [4-6]. It is worth noting that
ESRD is a disease with serious effects on the patients' QoL,
negatively affecting their social, financial and psychologi-
cal well-being [7,8].
Regarding relevant research, renal patients undergoing
HD or CAPD/PD treatment were found to experience QoL
deficits, while the areas affected were shown to be varied
[9,10]. Patients' health-related QoL in these two treatment
modalities was reported as being comparable; however
treatment-related differences were indicated in certain
QoL domains for each treatment modality respectively.
Findings are mixed with some studies showing that HD
patients report better physical well-being, sleep and sexual
relationships [11,12]. Such results were indicated for the
first two years of dialysis and over time [11,13,14]. How-
ever, adverse symptoms such as nocturnal distress and
inability to sleep during the nights leading up to dialysis
have also been reported by HD patients [15-17]. On the
other hand, compromised physical well-being in CAPD/
PD patients has been indicated in connection to lower lev-
els of albumin and health complications, e.g. peritonitis
[13,18,19].
Regarding mental health, HD patients have been found to
experience more depressive symptoms than PD [17,20].
Depression may be linked to the HD treatment modality,
since the patient has to be continually connected to the
haemodialysis machine during dialysis and so experience
significant restrictions in independent living [17,20]. In
addition, the rate of reported suicide in HD is higher,
while a substantial number of deaths resulting from die-
tary violations could also be accounted for as suicide
[21,22].
Furthermore, HD patients are reported to face psychoso-
cial problems, which can contribute to conflictions
between themselves and their medical carers. Such find-
ings could be attributed in part to the stressful conditions
in the HD treatment modality, including frequent visits
and prolonged waiting time in the dialysis unit
[17,23,24].
Regarding psychological dimensions in ESRD, it seems
that CAPD/PD patients are better adjusted than HD. This
may be due to the peritoneal treatment modality offering
increased autonomy and control, flexibility in everyday
life and the dietary regime, as well as fewer social restric-
tions [14,25-27]. PD patients have been found to report
better QoL ratings in specific areas like 'perceived ability
to travel', 'financial concerns', 'restriction in eating and
drinking' and 'dialysis access problems' [11]. Further-
more, PD patients have indicated more positive ratings in
several disease QoL domains, e.g. less kidney disease bur-
den, and being more encouraged and satisfied with care
[28].
It is recognized that regardless of the treatment method,
patients suffering from ESRD have to cope with many
adversities, e.g. physical symptoms, specific dietary
regimes and changes in their body image, while their con-
trol over treatment cannot always be predicted [29,30].
Such constraints are expected to affect the patients' life
and physical and social functioning, leading patients to
reconsider their personal and professional goals within
the context of living with a chronic illness. Subjective
issues of this kind can be investigated in patient-reported
health beliefs and in perceived physical, psychological
and social well-being.
Although a considerable number of articles on ESRD have
been published, there are a limited number of studies
comparing generic domains of QoL and mental health
factors, or health beliefs in HD and CAPD/PD patients. In
addition, the outcomes reported from QoL studies are fre-
quently inconclusive. The aim of the present study was to
investigate a) self-reported physical, psychological, social
and environmental well-being, b) mental health factors
such as anxiety and depression, as well as c) illness beliefs
of health locus of control in haemodialysis and peritoneal
dialysis patients. Differences were examined between
patients who recently commenced treatment and those on
long-term treatment (early and later years of current treat-
ment).
Method
The sample
A cohort of 144 end-stage renal disease patients were
recruited from dialysis units within three General Hospi-
tals located within the broader area of Athens. From this
cohort, 135 patients provided full data on the variables
studied, while the remaining 9 patients were excluded
having missing/incomplete data, which could be proba-
bly explained by advanced age (mean age of 67.16). The
cohort of 135 participants that participated in the analysis
consisted of: a) 77 patients (57.0%) undergoing in-centre
haemodialysis (HD) and b) 58 patients (43.0%) undergo-
ing continuous ambulatory peritoneal dialysis (CAPD/
PD), (the term PD will be used for the remainder of the
text). Patients within these two treatment modalities had
low comorbidity and were undergoing current dialysis for
a varied period of time. In this respect, participants could
be categorized into four distinct groups regarding current
treatment: a) HD patients who recently commenced treat-BMC Nephrology 2008, 9:14 http://www.biomedcentral.com/1471-2369/9/14
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ment (< 4 years), b) HD patients on long term treatment
(> 4), c) PD patients who recently commenced treatment
(< 4 years) and d) PD on long term treatment (> 4). A cut-
off period of 4 years of treatment was agreed upon by the
researchers because it was considered that a period of 3–4
years is required for patient adjustment to the diagnosis
and treatment of a chronic illness. The group of HD
patients with greater than 4 years of treatment included
participants with a higher mean length of treatment meas-
ured in years (12.65 ± 6.64) in comparison to the respec-
tive group of PD patients (5.82 ± 1.13).
Sociodemographic characteristics of these groups are pre-
sented in Table 1.
Next, in order to investigate differences between the HD
and PD treatment modalities without the possible effect
of length of treatment, 41 cases of HD and 48 cases of PD
patients were selected from the total cohort of 135 partic-
ipants according to specified criteria to formulate two
equivalent groups. Selection criteria included the patient
commencing dialysis treatment within a 4 year period and
ensured a balanced ratio of male/female participants
within the two groups. Following the selection procedure,
the two groups were tested for significant differences
regarding sociodemographic variables. As seen in Table 2,
the groups can be considered equivalent with no statisti-
cally significant differences between them (p. > 0.05).
All participants were of Greek nationality who gave signed
consent for participation in the study. They had been
informed of their rights to refuse or to discontinue partic-
ipating in the study according to the ethical standards of
the Helsinki Declaration (1983) [31]. Ethical permission
for the study was obtained from the scientific committees
of the participating hospitals.
Instruments
The following measurement tools were administered to
all patients:
1) The World Health Organization Quality of Life question-
naire (WHOQOL-BREF) [32]. It is a self-report inventory
of generic QoL with 26 original items and 4 additional
items derived from the validation of the instrument
within Greek populations [33,34]. The items fall into four
domains: a) Physical Health, b) Psychological Health, c)
Social Relationships and d) Environment, while two items
provide a measurement of an Overall QoL/Health facet.
Table 1: Descriptive characteristics of HD and PD patients in early and later years of treatment.
HD
< 4 years of treatment
N = 39
HD
> 4 years of treatment
N = 38
PD
< 4 years of treatment
N = 41
PD
> 4 years of treatment
N = 17
Age (years)
21–40 10 (25.6%) 5 (13.1%) 3 (7.3%) 0 (0%)
41–60 14 (35.8%) 9 (23.6%) 13 (31.7%) 6 (35.2%)
> 60 15 (38.4%) 24 (63.1%) 25 (60.9%) 11 (64.7%)
Total 39 (100.0%) 38(100.0%) 41(100.0%) 17(100.0%)
Mean ± SD 52. 95 ± 16.66 60.53 ± 13.59 62.71 ± 13.37 67.06 ± 9.21
Gender
Male 29 (74.3%) 22 (57.8%) 22 (53.6%) 7 (41.1%)
Female 10 (25.6%) 16 (42.1%) 19 (46.3%) 10 (58.8%)
Total 39 (100.0%) 38(100.0%) 41(100.0%) 17(100.0%)
Marital status
Single 11(28.2%) 8 (21.0%) 5 (12.1%) 1(5.8%)
Married 26 (66.6%) 26 (68.4%) 34 (82.9%) 13 (76.4%)
D/W/R* 2 (5.1%) 4 (10.5%) 2 (4.8%) 3 (17.6%)
Total 39(100.0%) 38(100.0%) 41(100.0%) 17(100.0%)
Education
Elementary 17 (43.5%) 21(55.2%) 12(29.2%) 8 (47.0%)
Secondary 17(43.5%) 8 (21.0%) 20 (48.7%) 9 (52.9%)
University 5 (12.8%) 9 (23.6%) 9 (21.9%) 0 (0%)
Total 39(100.0%) 38(100.0%) 41(100.0%) 17(100.0%)
Mean ± SD 8.44 ± 4.15 8.37 ± 5.0 10.61 ± 3.9 7.76 ± 3.5
Length of treatment
Mean ± SD 2.10 ± 1.16 12.65 ± 6.64 2.17 ± 1.13% 5.82 ± 1.13
*D/W/R = Divorced/Widowed/RoommateBMC Nephrology 2008, 9:14 http://www.biomedcentral.com/1471-2369/9/14
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The scale has demonstrated good internal consistency
with Cronbach's alpha ranging from 0.67 – 0.81 per
domain. It is rated on a 5-point Likert scale and the range
of scores is between 1–20 with higher scores indicating
better QoL.
2) The General Health Questionnaire (GHQ-28) is a widely
used self-report measure of general health, developed by
Goldberg (1978) [35]. The questionnaire has demon-
strated good psychometric properties within Greek popu-
lations (internal consistency, validity with indices of
sensitivity, specificity, positive predictive value, negative
predictive value and overall misclassification rate) [36].
Besides being used as a screening tool for psychiatric cases
in medical settings and general practice, it may also be
used to identify self-perceived differences in mental
health. The 28-item version used in this study consists of
four sub-scales: a) somatic symptoms, b) anxiety/insomnia, c)
social dysfunction and d)  severe depression. Lower scores
indicate better mental health.
3) The Multidimensional Health Locus of Control (MHLC) is
a self-report inventory measuring beliefs on health locus
of control. It consists of 18 items, grouped into four fac-
tors representing four categories of health beliefs: a) inter-
nal health locus, b) chance, c) doctors and d) important others.
The last three refer to external health locus of control
[37,38]. The four factors are not mutually exclusive and
scores may weight in a particular direction. Higher scores
in one factor indicate a stronger presence of beliefs in the
specific dimension. The questionnaire has been translated
into Greek and is under validation. Preliminary evidence
shows that the 4 factor model of internal, chance, doctors
and powerful others may fit within the data with Cron-
bach's alpha ranging from 0.50 – 0.85 (authors' commu-
nication).
Statistical Analysis
Kolmogorov-Smirnov tests were performed in order to
check whether the values of the sample would fall within
a normal distribution. Next, the analyses performed
aimed to:
a) Investigate differences between patients who had
recently commenced treatment and those on long term
treatment within the HD and PD modalities. Thus, one-
Way ANOVA analysis was performed to investigate differ-
ences within patients falling into 4 categories according to
treatment modality and length of treatment. Investigation
of differences included QoL domains, mental health and
illness beliefs with regards to health locus of control. Next,
independent Samples T-tests were performed to check dif-
ferences between patients who recently commenced treat-
ment and those on long term treatment within each
Table 2: Characteristics of HD and PD patients selected to form equivalent groups.
HD
N = 41 (46.06%)
PD
N = 48 (53.9%)
p-value
Age (years)
Mean ± SD 65.34 ± 8.37 64.10 ± 10.36 NS
Gender
Male 21 (51.30%) 23 (47.90%) NS
Female 20 (48.70%) 25 (52.10%)
Total 41 (100.0%) 48 (100.0%)
Marital status
Single 4 (9.75%) 6 (12.50%) NS
Married 33 (80.48%) 38 (79.20%)
D/W/R* 4 (9.75%) 4 (8.30%)
Total 41 (100.0%) 48 (100.0%)
Education
0–9 years 29 (70.73%) 26 (54.16%) NS
> 9 years 12 (29.27%) 22 (45.84%)
Total 41 (100.0%) 48 (100.0%)
Length of dialysis treatment (years)
Mean ± SD 4.15 ± 2.57 3.62 ± 2.00 NS
*D/W/R = Divorced/Widowed/Roommate
NS = p > 0.05
This table displays the results of the Independent-Samples T-Test demonstrating that there are no statistically significant differences between the 
HD and PD groups, including patients who were selected according to specified criteria of being in the initial stages of treatment and having similar 
socio-demographic characteristics.BMC Nephrology 2008, 9:14 http://www.biomedcentral.com/1471-2369/9/14
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treatment modality. Also, ANCOVA analysis was per-
formed controlling for length of treatment in the PD and
HD patients.
b) Investigate differences between HD and PD patients,
using two groups comprised of selected cases from the
total cohort of 135 patients, equivalent for length of treat-
ment and sociodemographic characteristics. Independent
Samples T-tests were performed in order to check for sig-
nificant differences in all variables investigated in the
study.
Results
The values of the total cohort were found to pass the nor-
mality distribution test. Regarding differences within the
four patient groups consisting of HD and PD patients who
recently commenced and those on long term treatment
(early/later years of treatment), One-Way ANOVA analy-
sis was conducted. The results of this test reveal that HD
patients with more than 4 years of current treatment var-
ied significantly from the other patient groups indicating
lower QoL mean scores in the WHOQOL-BREF domains
of  physical health, social relationships and  environment
(Table 3).
In addition, according to the means of the GHQ-28 sub-
scales, the group of HD patients with less than 4 years of
treatment indicated the highest level of anxiety and insom-
nia, while those with more than 4 years of treatment indi-
cated the highest mean in the GHQ-28 total score,
signifying poorer overall mental health (Table 3).
A series of independent samples T-tests were then per-
formed between the groups of patients who recently com-
menced and those in long term treatment and for each
modality separately. Significant differences were found
between the groups of the patients in the HD treatment
modality. Specifically, HD patients on long term treat-
ment had significantly lower scores in the domains of
physical, psychological and social well-being. On the other
hand, no significant differences in QoL and mental health
parameters were found between the two PD groups of
patients. It should be noted that differences in length of
treatment between the PD groups were not as great as
between the HD groups (approximately 3.5 years and 10
years respectively) as mentioned before and seen in Table
1.
Concerning illness beliefs with regards to health locus of
control, the group of HD patients who had recently com-
menced treatment differed significantly from patients in
the other categories, indicating the highest mean scores in
the dimension of internal heath locus of control (mean
scores and p-values can be seen in Table 3). As for the
Table 3: WHOQOL-BREF, GHQ-28 and MHLC in HD and PD patients in early and later years of treatment.
WHOQOL-BREF 
domains
HD
< 4 years of 
treatment(N = 39)
M ± SD
HD
> 4 years of 
treatment (N = 38)
M ± SD
PD
< 4 years of 
treatment (N = 41)
M ± SD
PD
> 4 years of 
treatment(N = 17)
M ± SD
p-value
Physical 13.86 ± 3.16 11.95 ± 3.76 13.92 ± 2.87 13.07 ± 2.80 0.03*
Psychological 14.34 ± 3.02 12.29 ± 3.96 13.23 ± 3.01 13.64 ± 3.35 NS
Social relationships 13.88 ± 2.86 11.77 ± 4.05 14.13 ± 2.33 13.56 ± 2.54 0.00*
Environment 13.05 ± 2.64 12.65 ± 2.82 14.69 ± 1.76 14.05 ± 1.82 0.00*
Overall QoL/health 3.10 ± 0.97 2.88 ± 1.18 3.16 ± 0.79 3.11 ± 0.91 NS
GHQ – 28 subscales
Somatic symptoms 1.76 ± 0.52 1.94 ± 0.54 1.66 ± 0.52 1.78 ± 0.54 NS
Anxiety/insomnia 1.95 ± 0.68 1.87 ± 0.62 1.49 ± 0.54 1.49 ± 0.72 0.00*
Social dysfunction 2.22 ± 0.51 2.35 ± 0.43 2.17 ± 0.31 2.20 ± 0.47 NS
Severe depression 1.46 ± 0.64 1.64 ± 0.80 1.28 ± 0.53 1.32 ± 0.63 NS
Total score 1.85 ± 0.45 1.95 ± 0.50 1.65 ± 0.42 1.80 ± 0.48 0.04*
Health Locus of 
Control factors
Internal locus 27.82 ± 6.20 25.67 ± 7.33 25.10 ± 8.03 21.46 ± 8.41 0.04*
Chance 25.15 ± 8.33 23.59 ± 7.63 20.94 ± 8.87 28.40 ± 7.90 0.01*
Doctors 16.23 ± 2.42 15.43 ± 2.84 17.25 ± 1.35 16.26 ± 2.08 0.00*
Important others 12.38 ± 4.21 11.64 ± 4.43 12.51 ± 4.31 11.06 ± 5.76 NS
*p < 0.05; N = 135.
This table displays the results of One-Way ANOVA demonstrating differences between HD and PD patients classified into the categories of 
patients who recently commenced treatment and patients on long term treatment.BMC Nephrology 2008, 9:14 http://www.biomedcentral.com/1471-2369/9/14
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groups of PD patients, those with more than 4 years of
treatment indicated the highest mean score in the dimen-
sion of chance. Concerning the dimension of doctors, sig-
nificant differences among the four groups were
indicated. So, it is observed that HD patients with more
than 4 years of treatment have the lowest mean score,
while PD patients who had recently commenced treat-
ment have the highest mean score in this dimension.
In order to test for the effect of length of treatment,
ANCOVA analysis was applied controlling for years of
treatment in the total cohort. The effect was observed in
the WHOQOL-BREF domain of environment, in the GHQ-
28 subscales of anxiety/insomnia and severe depression and
in the dimensions of internal and doctors regarding health
locus of control.
The analysis conducted up to this point reveals that the
variable of length of treatment plays a significant role in
the patients' quality of life. Consequently, differences
between HD and PD patients were further examined using
the selective criteria of less than 4 years of treatment com-
bined with similar sociodemographic characteristics.
Based on selection of cases from the total cohort, two
equivalent groups were formed comprising of PD and HD
patients and were tested for significant differences. Inde-
pendent Samples T-test provided evidence of no signifi-
cant differences in gender, age, marital status, education
and length of treatment. Table 2 shows the characteristics
of these groups.
Following investigation into QoL and mental health,
independent samples T-tests were then performed
between the two groups of patients showing statistically
significant differences. Specifically, HD patients indicated
significantly lower QoL scores in the environment domain
of WHOQOL-BREF. Furthermore, they reported signifi-
cantly higher scores in the GHQ-28 sub-scales of anxiety/
insomnia, severe depression and the total GHQ-28 score (See
Table 4).
With regards to illness beliefs, a significant difference was
observed with HD patients presenting higher scores in the
dimension of internal health locus of control. Both groups
presented a similar pattern of illness beliefs, according to
which higher values were identified in the internal and
chance dimensions followed by the dimensions of doctors
and important others (See Table 4).
Discussion
Deterioration in quality of life is particularly evident in
the HD group of patients who have been on dialysis for an
extended period of time. Most quality of life domains
seem to be affected, including overall mental health. After
taking into consideration that QoL deficits were mostly
indicated by HD patients who had been on long term
treatment, it could be argued that these patients experi-
enced significant QoL changes over time, including dete-
rioration in physical, social and environmental well-being as
well as in overall mental health. In the relevant literature,
it has been suggested that health-related QoL was more
Table 4: WHOQOL-BREF, GHQ-28 and MHLC in HD and PD equivalent groups.
WHOQOL-BREF domains HD patients (N = 41)
M ± SD
PD patients (N = 48)
M ± SD
p-value
Physical 12.44 ± 3.78 13.46 ± 2.78 NS
Psychological 12.91 ± 3.51 13.16 ± 3.16 NS
Social relationships 13.06 ± 2.89 13.69 ± 2.21 NS
Environment 12.95 ± 2.63 14.35 ± 1.83 0.00*
Overall QoL/health 2.98 ± 0.98 3.11 ± 0.84 NS
GHQ-28 subscales
Somatic symptoms 1.86 ± 0.58 1.73 ± 0.55 NS
Anxiety/insomnia 1.87 ± 0.69 1.53 ± 0.64 0.02*
Social dysfunction 2.36 ± 0.55 2.22 ± 0.36 NS
Severe depression 1.65 ± 0.88 1.32 ± 0.60 0.04*
Total score 1.93 ± 0.57 1.70 ± 0.48 0.04*
Health Locus of Control factors
Internal locus 27.36 ± 7.00 23.15 ± 8.35 0.01*
Chance 25.21 ± 8.65 23.22 ± 9.16 NS
Doctors 16.48 ± 2.27 16.80 ± 1.72 NS
Important others 13.21 ± 4.56 11.80 ± 4.77 NS
*p < 0.05; N = 89.
This table displays the results of the Independent-Samples T-Test demonstrating differences between HD and PD patients groups, both in initial 
stages of treatment and with similar socio-demographic characteristics.BMC Nephrology 2008, 9:14 http://www.biomedcentral.com/1471-2369/9/14
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compromised in HD patients, which may only become
evident as time on therapy increases [39].
In particular, HD patients seem to experience a higher
level of adverse symptoms such as anxiety and insomnia
during the initial years of treatment, which may reflect the
patient's emotional burden in having to adhere to a strict
treatment regimen. It is suggested that longitudinal stud-
ies using samples that can be available over time, may be
useful for overcoming cross-sectional limitations and
acquiring robust evidence on QoL differences between
HD and PD treatment modalities over a period of time.
This is an issue of increased interest as there is evidence for
changes in QoL, including a more favourable effect of HD
treatment on the patients' physical well being over the
first year [11]. However, it not known whether this
improvement is maintained.
Regarding the PD groups, differences in QoL and mental
health between patients who recently commenced and
those on long term treatment are not significant. How-
ever, one should take into consideration that the PD
groups of this sample did not have a large difference in
terms of length of treatment, as was the case with the HD
groups. It is argued that quality of life differences linked to
modality without taking into consideration the time fac-
tor may restrict our understanding of differences and
changes in QoL over time.
Following this line of thought, QoL controlling for the
effects of length of treatment was investigated (ANCOVA).
Accordingly, it was observed that patients' quality of life
was only affected in the environment domain, and in the
anxiety/insomnia  dimension of mental health. Focusing
further on the differences between HD and PD patient
groups, both in initial stages of treatment, it became evi-
dent that QoL deficits in these two treatment modalities
were more limited.
Accordingly, HD patients reported a more compromised
quality of life indicating a higher dissatisfaction with dif-
ferent aspects of their environment. Specifically, these
patients reported experiencing various difficulties, includ-
ing a more negative opinion about availability and quality
of health services. Also, they reported increased dissatisfac-
tion with their finances, opportunities for recreation, means of
transportation, as well as opportunities for acquiring everyday
living information and new skills. Deficits in this area of QoL
may be associated with treatment, since in-center haemo-
dialysis imposes serious restrictions on the patient's life
due to dependence on the dialysis machine. Also, dissatis-
faction with health services may reflect the burden experi-
enced by these patients, including stressful conditions
during the dialysis procedure, high frequency of received
in-center treatment and prolonged waiting-time in the
unit [17,23,24]. It is noted that the WHOQOL-BREF
domain of environment and the facets mentioned above
seem to accurately represent the dimensions, which may
be seriously affected by dialysis treatment procedures.
These results correspond to previous findings showing
that it is the PD patients who report better ratings in 'per-
ceived ability to travel', 'financial concerns', and 'dialysis
access' [11], indicating increased satisfaction with their
health care [28].
Furthermore, focusing on differences between HD and PD
equivalent groups of patients in initial stages of treatment,
HD patients reported more symptoms of anxiety, sleeping
problems, depression or suicidal ideation. Problems or pat-
terns of sleep are a central issue for many disorders and
they are frequently addressed for ill as well as healthy pop-
ulations [11,40]. Regarding the comparatively higher level
of suicidal thoughts reported by this category of patients,
this is a finding in agreement with international literature
indicating higher rates of suicidal attempts in HD patients
[21,22]. However, findings in the relevant literature are
mixed regarding physical and psychological well-being
and certain studies have suggested that HD patients
reported a more positive evaluation of their physical well-
being [12].
Regarding health beliefs, HD patients indicated a greater
preference for the internal dimension focusing more on
their own personal control to regulate their health condi-
tion (Table 4). This may reflect a stronger need of these
patients to counterbalance the imposed dependence on
the dialysis procedure and the restrictive dietary regimen
by exercising control over their illness. Also, it could be
the case that beliefs focusing on personal control and
responsibility over one's condition could indicate self-
blame and depressive mood. HD patients are reported in
the relevant literature to present depressive symptomatol-
ogy [17,20]. Further investigation into these hypotheses is
necessary.
With regard to PD patients, it is worth noting that patients
on long term treatment indicated a higher preference for
the dimension of chance on health locus of control (Table
3). It may be argued that as time of treatment increases,
PD patients seem to change their illness beliefs and rely
less on human and professional aspects regarding their
medical care, instead turning to beliefs of power stem-
ming from unpredictable external factors, like chance. This
finding may be interpreted as the patients wishing to dis-
tance themselves from medical carers. If this is the case, it
should be addressed appropriately by the health profes-
sionals involved in the peritoneal dialysis treatment of the
participating dialysis units.BMC Nephrology 2008, 9:14 http://www.biomedcentral.com/1471-2369/9/14
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In addition, based on the means of the groups seen in the
ANOVA (Table 3), PD patients in their initial stages of
treatment seem to rely more on their doctors  than the
patients in the other categories. This finding may reflect
the need of PD patients to rely more on the help of their
medical helpers for undertaking the required training in
peritoneal dialysis procedures as they are entering PD
treatment.
In general, HD patients appear to endorse a more stable
pattern of illness beliefs over time, as these patients, both
those recently commenced and those on long term treat-
ment appear to hold a similar weighting in the dimen-
sions of health locus of control.
It is worth noting that findings in the area of illness beliefs
of control are very limited. The results of one study
reported in the literature, indicated no differences
between HD and PD patients' health locus of control [41].
This psychological dimension has been well examined in
HD patients in relation to adherence [42]. It is necessary
however to take into consideration that methodological
issues may account for differential findings, one of which
is the possible cultural differences between the patient
samples. It is suggested that examining cross-cultural dif-
ferences regarding heath beliefs and attitudes in ESRD
patients may provide answers to some of these queries.
This study has demonstrated that different QoL deficits,
mental health problems and illness beliefs may character-
ize PD and HD patients. The findings of the present study
could be used in the development of health care services
and in-patient management. The role of health beliefs in
particular may play an important role in the course of ill-
ness and treatment outcomes and could therefore be iden-
tified as a new area for psychological intervention in
people with End Stage Renal Disease [43,44].
Limitations
Limitations of the study may include the lack of investi-
gating the effect of clinical factors such as adequacy of
dialysis, hemoglobin level or other clinical parameters on
the patients' perceptions of quality of life and mental
health. The focus of the study however, was on QoL differ-
ences and adverse symptoms in HD and PD patients who
recently commenced and those on long-term treatment.
Conclusion
The main focus of the present study was to examine QoL
in HD and PD patients and investigate differences
between patients who recently commenced and those on
long-term treatment. The results of the study provide evi-
dence that the HD on long term of treatment had
increased deficits in physical, social and environmental QoL,
as well as in mental health.
Further, patients who had similar length of current treat-
ment in the two treatment modalities, differ only with
regards to their environmental well-being. Thus, in relation
to differences between patients in early and later years of
treatment, it appears that QoL deficits in HD patients
become more extended over time, and seem to be more
precisely signified by the factors in the environmental QoL
domain. It may be argued that HD patients on long term
dialysis appear to be more seriously compromised in their
quality of life and mental health.
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